Patients on Itovebi plus Ibrance and fulvestrant had improved progression-free and overall survival compared to Ibrance-fulvestrant alone.

Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...

Men on active surveillance for low- to intermediate-risk prostate cancer (PCa) have low risk for PCa-related mortality at a median follow-up of 18 years. However, a majority of men do progress and ...

Researchers at Keele University have published the first investigation into the variation in the chemical makeup of calcifications caused by prostate cancer, in the hope of identifying new markers to ...

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent ...

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 ...

Results of a study led by VHIO’s Prostate Cancer Group suggest that treatment with CDK4/6 inhibitors followed by senloytic ...

Novartis AG (NYSE:NVS) is a Swiss pharmaceutical leader focused on developing innovative treatments across oncology, ...

Johnson & Johnson (NYSE:JNJ) is a global healthcare leader with a diverse portfolio across pharmaceuticals, medical devices, ...

Jacob E. Berchuck, MD, highlights novel findings pointing to androgen receptor signaling and Wnt pathway activation as key ...

Once seen as a niche tool for rare tumors, theranostics is quickly becoming a new standard in cancer care. Combining diagnostics and therapy in a single platform, the field has drawn billions in ...